How does Lipoprotein(a) influence ASCVD risk and how is it managed?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Lp(a) contributes to ASCVD risk independently of other lipids, and its levels are largely determined by genetics rather than diet or simple lifestyle changes. In clinical management, lowering Lp(a) itself is challenging. Statins primarily reduce LDL-C and have only a modest or variable effect on Lp(a). PCSK9 inhibitors can modestly lower Lp(a) by about a quarter to a third while also lowering LDL-C. Antisense therapies targeting apo(a) are in development and have shown more substantial Lp(a) reductions in studies, representing a promising approach for patients with very high Lp(a) despite standard therapy. Diet and most traditional lipid drugs do not meaningfully reduce Lp(a); bile acid sequestrants may lower it slightly, but they are not the primary strategy for addressing Lp(a) risk. Therefore, the best-supported statement is that Lp(a) is an independent ASCVD risk factor, with management that includes statins and PCSK9 inhibitors (modestly lowering Lp(a)) and with antisense therapies in development to achieve greater reductions.